MGMT and glioblastoma: Temozolomide sensitivity in glioblastoma patients correlates with the expression and promoter methylation status of O-6-methylguanine-DNA methyltransferase (MGMT) [32], an enzyme that counteracts temozolomide-induced DNA damage.